{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:46Z","timestamp":1792799506772,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"17","funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT RP140102"],"award-info":[{"award-number":["CPRIT RP140102"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Conquer Cancer Foundation\u2014Gianni Bonadonna Breast Cancer Research Fellowship","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breast Cancer Specialized Programs of Research Excellence","award":["P50CA186784"],"award-info":[{"award-number":["P50CA186784"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Cancer Center Support","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}]},{"name":"NCI Cancer Center Support","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP120092"],"award-info":[{"award-number":["RP120092"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4\/6i) are highly effective against estrogen receptor\u2013positive (ER+)\/HER2\u2212 breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of sensitivity and resistance to CDK4\/6i may lead to identification of predictive biomarkers and novel therapeutic targets, paving the way toward improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Parental breast cancer cells and their endocrine-resistant derivatives (EndoR) were used. Derivatives with acquired resistance to palbociclib (PalboR) were generated from parental and estrogen deprivation\u2013resistant MCF7 and T47D cells. Transcriptomic and proteomic analyses were performed in palbociclib-sensitive and PalboR lines. Gene expression data from CDK4\/6i neoadjuvant trials and publicly available datasets were interrogated for correlations of gene signatures and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Parental and EndoR breast cancer lines showed varying degrees of sensitivity to palbociclib. Transcriptomic analysis of these cell lines identified an association between high IFN signaling and reduced CDK4\/6i sensitivity; thus an \u201cIFN-related palbociclib-resistance Signature\u201d (IRPS) was derived. In two neoadjuvant trials of CDK4\/6i plus endocrine therapy, IRPS and other IFN-related signatures were highly enriched in patients with tumors exhibiting intrinsic resistance to CDK4\/6i. PalboR derivatives displayed dramatic activation of IFN\/STAT1 signaling compared with their short-term treated or untreated counterparts. In primary ER+\/HER2\u2212 tumors, the IRPS score was significantly higher in lumB than lumA subtype and correlated with increased gene expression of immune checkpoints, endocrine resistance, and poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Aberrant IFN signaling is associated with intrinsic resistance to CDK4\/6i. Experimentally, acquired resistance to palbociclib is associated with activation of the IFN pathway, warranting additional studies to clarify its involvement in resistance to CDK4\/6i.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-19-4191","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:25:26Z","timestamp":1612351526000},"page":"4870-4882","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4\/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer"],"prefix":"10.1158","volume":"27","author":[{"given":"Carmine","family":"De Angelis","sequence":"first","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"4Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0005-6496","authenticated-orcid":false,"given":"Xiaoyong","family":"Fu","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"12Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Cataldo","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"4Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Nardone","sequence":"additional","affiliation":[{"name":"5Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resel","family":"Pereira","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamunarani","family":"Veeraraghavan","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmistha","family":"Nanda","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Qin","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidyalakshmi","family":"Sethunath","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-7160","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7962-673X","authenticated-orcid":false,"given":"Susan G.","family":"Hilsenbeck","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-356X","authenticated-orcid":false,"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[{"name":"6\u201cSandro Pitigliani\u201d Translational Research Unit, Hospital of Prato, Prato, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Migliaccio","sequence":"additional","affiliation":[{"name":"6\u201cSandro Pitigliani\u201d Translational Research Unit, Hospital of Prato, Prato, Italy."},{"name":"7\u201cSandro Pitigliani\u201d Medical Oncology Department, Hospital of Prato, Prato, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Guarducci","sequence":"additional","affiliation":[{"name":"5Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."},{"name":"6\u201cSandro Pitigliani\u201d Translational Research Unit, Hospital of Prato, Prato, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-2997","authenticated-orcid":false,"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[{"name":"6\u201cSandro Pitigliani\u201d Translational Research Unit, Hospital of Prato, Prato, Italy."},{"name":"7\u201cSandro Pitigliani\u201d Medical Oncology Department, Hospital of Prato, Prato, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey M.","family":"Litchfield","sequence":"additional","affiliation":[{"name":"8Eli Lilly and Company, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2800-077X","authenticated-orcid":false,"given":"Jiangang","family":"Liu","sequence":"additional","affiliation":[{"name":"8Eli Lilly and Company, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Donaldson","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier","family":"Selenica","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Brown","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben H.","family":"Park","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"11University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[{"name":"11University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mothaffar F.","family":"Rimawi","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"12Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"8Eli Lilly and Company, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-7529","authenticated-orcid":false,"given":"Rinath","family":"Jeselsohn","sequence":"additional","affiliation":[{"name":"5Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Kent","family":"Osborne","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"12Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1696-5213","authenticated-orcid":false,"given":"Rachel","family":"Schiff","sequence":"additional","affiliation":[{"name":"1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas."},{"name":"2Department of Medicine, Baylor College of Medicine, Houston, Texas."},{"name":"3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas."},{"name":"12Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"2022061020212442400_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-017-0591-8","article-title":"The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer","volume":"19","author":"Jeselsohn","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2022061020212442400_bib2","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"key":"2022061020212442400_bib3","doi-asserted-by":"crossref","first-page":"1758835918786451","DOI":"10.1177\/1758835918786451","article-title":"CDK4\/6 inhibition in breast cancer: current practice and future directions","volume":"10","author":"Pernas","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2022061020212442400_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41416-018-0354-9","article-title":"The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance","volume":"120","author":"Nardone","year":"2019","journal-title":"Br J Cancer"},{"key":"2022061020212442400_bib5","doi-asserted-by":"crossref","first-page":"E6600","DOI":"10.1073\/pnas.1612835113","article-title":"FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer","volume":"113","author":"Fu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061020212442400_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","article-title":"Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer","volume":"4","author":"Guarducci","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"2022061020212442400_bib7","first-page":"2321","article-title":"Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines","volume":"56","author":"Pink","year":"1996","journal-title":"Cancer Res"},{"key":"2022061020212442400_bib8","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","article-title":"Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer","volume":"25","author":"Kettner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib9","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"2022061020212442400_bib10","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat Commun"},{"key":"2022061020212442400_bib11","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","article-title":"Molecular pathways: interferon\/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth","volume":"18","author":"Khodarev","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib12","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-17-2551","article-title":"Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer","volume":"24","author":"Post","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib13","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase 2 neoadjuvant study in HR+\/HER2- breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib15","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2022061020212442400_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"2022061020212442400_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1101\/gad.580710","article-title":"Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling","volume":"24","author":"van Harn","year":"2010","journal-title":"Genes Dev"},{"key":"2022061020212442400_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature25507","article-title":"Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress","volume":"555","author":"Macheret","year":"2018","journal-title":"Nature"},{"key":"2022061020212442400_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2013.01.039","article-title":"STING recognition of cytoplasmic DNA instigates cellular defense","volume":"50","author":"Abe","year":"2013","journal-title":"Mol Cell"},{"key":"2022061020212442400_bib20","doi-asserted-by":"crossref","first-page":"68012","DOI":"10.18632\/oncotarget.12010","article-title":"A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer","volume":"7","author":"Malorni","year":"2016","journal-title":"Oncotarget"},{"key":"2022061020212442400_bib21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/2159-8290.CD-16-1179","article-title":"Loss of MutL disrupts CHK2-dependent cell-cycle control through CDK4\/6 to promote intrinsic endocrine therapy resistance in primary breast cancer","volume":"7","author":"Haricharan","year":"2017","journal-title":"Cancer Discov"},{"key":"2022061020212442400_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol"},{"key":"2022061020212442400_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000484167","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors in breast cancer and potential biomarkers of response","volume":"12","author":"Guarducci","year":"2017","journal-title":"Breast Care"},{"key":"2022061020212442400_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","article-title":"An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients","volume":"123","author":"Gy\u00f6rffy","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022061020212442400_bib25","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"2022061020212442400_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","article-title":"Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"2022061020212442400_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2022061020212442400_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3389\/fimmu.2017.01097","article-title":"Regulation of human macrophage M1-M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1","volume":"8","author":"Raggi","year":"2017","journal-title":"Front Immunol"},{"key":"2022061020212442400_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022061020212442400_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2022061020212442400_bib31","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061020212442400_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bjc.6602699","article-title":"Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles","volume":"93","author":"Rickardson","year":"2005","journal-title":"Br J Cancer"},{"key":"2022061020212442400_bib33","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41388-018-0624-2","article-title":"Type I interferon\/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer","volume":"38","author":"Lan","year":"2019","journal-title":"Oncogene"},{"key":"2022061020212442400_bib34","first-page":"6540","article-title":"Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells","volume":"61","author":"Luker","year":"2001","journal-title":"Cancer Res"},{"key":"2022061020212442400_bib35","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.celrep.2017.02.037","article-title":"CD95\/Fas increases stemness in cancer cells by inducing a STAT1-dependent type I interferon response","volume":"18","author":"Qadir","year":"2017","journal-title":"Cell Rep"},{"key":"2022061020212442400_bib36","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1073\/pnas.0308102100","article-title":"STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells","volume":"101","author":"Khodarev","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061020212442400_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13058-014-0506-7","article-title":"Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death","volume":"17","author":"Choi","year":"2015","journal-title":"Breast Cancer Res"},{"key":"2022061020212442400_bib38","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib39","doi-asserted-by":"crossref","first-page":"77205","DOI":"10.18632\/oncotarget.12858","article-title":"Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents","volume":"7","author":"Gaston","year":"2016","journal-title":"Oncotarget"},{"key":"2022061020212442400_bib40","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"2022061020212442400_bib41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2022061020212442400_bib42","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022061020212442400_bib43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"2022061020212442400_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 trial (Alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061020212442400_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2022061020212442400_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2017.07.005","article-title":"Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art","volume":"35","author":"Solinas","year":"2017","journal-title":"Breast"},{"key":"2022061020212442400_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1471-2407-14-257","article-title":"High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer","volume":"14","author":"Tymoszuk","year":"2014","journal-title":"BMC Cancer"},{"key":"2022061020212442400_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2018.00049","article-title":"Targeting macrophages in cancer: from bench to bedside","volume":"8","author":"Poh","year":"2018","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.1158\/1078-0432.ccr-21-2431","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/27\/17\/4870\/3092348\/4870.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/27\/17\/4870\/3092348\/4870.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T20:18:24Z","timestamp":1654892304000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/27\/17\/4870\/671633\/Activation-of-the-IFN-Signaling-Pathway-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":48,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,2,3]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-4191","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22481027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22481033.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22481033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6530603","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6530603.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22481030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22481030.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22481027.v1","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}